Article
Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.
Clinical pharmacokinetics - 1 Jan 2017
Gopalakrishnan Sathej M, Polepally Akshanth R, Mensing Sven, Khatri Amit, Menon Rajeev M
Abstract excerpt
BACKGROUND AND OBJECTIVE: Hepatitis C virus (HCV) infection is of considerable clinical concern in Japan. We modeled the population pharmacokinetics of an oral interferon-free, direct-acting antiviral agent (DAA) regimen (i.e., the 2D regimen) recently approved for the treatment of chronic HCV genotype 1 infection as a new option for affected Japanese patients. METHODS: Using data from a phase III clinical trial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.